CN103154026B - 抗il-17的抗体 - Google Patents

抗il-17的抗体 Download PDF

Info

Publication number
CN103154026B
CN103154026B CN201180048098.2A CN201180048098A CN103154026B CN 103154026 B CN103154026 B CN 103154026B CN 201180048098 A CN201180048098 A CN 201180048098A CN 103154026 B CN103154026 B CN 103154026B
Authority
CN
China
Prior art keywords
seq
antibody
residue
amino acid
aminoacid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180048098.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103154026A (zh
Inventor
R·霍里克
D·金
P·鲍尔斯
J·道尔顿
B·吴
T·罗伯茨
X·张
L·阿尔托贝尔三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anaptysbio Inc
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of CN103154026A publication Critical patent/CN103154026A/zh
Application granted granted Critical
Publication of CN103154026B publication Critical patent/CN103154026B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
CN201180048098.2A 2010-08-05 2011-08-02 抗il-17的抗体 Active CN103154026B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37097810P 2010-08-05 2010-08-05
US61/370,978 2010-08-05
PCT/US2011/046201 WO2012018767A2 (en) 2010-08-05 2011-08-02 Antibodies directed against il-17

Publications (2)

Publication Number Publication Date
CN103154026A CN103154026A (zh) 2013-06-12
CN103154026B true CN103154026B (zh) 2016-07-06

Family

ID=45560018

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180048098.2A Active CN103154026B (zh) 2010-08-05 2011-08-02 抗il-17的抗体

Country Status (10)

Country Link
US (1) US9328166B2 (https=)
EP (1) EP2601217B1 (https=)
JP (1) JP2013537414A (https=)
CN (1) CN103154026B (https=)
AU (1) AU2011285922B2 (https=)
BR (1) BR112013002831A2 (https=)
ES (1) ES2633145T3 (https=)
NZ (1) NZ607615A (https=)
RU (1) RU2595385C2 (https=)
WO (1) WO2012018767A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
CN109053884A (zh) * 2015-11-02 2018-12-21 东南大学 Wasabi蛋白纳米抗体及其编码序列与应用
CN107236041B (zh) * 2016-03-29 2020-07-24 舒泰神（北京）生物制药股份有限公司 Il-17抗体
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP3965818A4 (en) 2019-05-08 2023-05-31 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY
AR123935A1 (es) * 2020-10-28 2023-01-25 Janssen Biotech Inc COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
CN112646030B (zh) * 2021-01-11 2021-11-30 内蒙古创润生物科技有限公司 一种包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
CN121731462A (zh) * 2024-09-27 2026-03-27 百奥泰生物制药股份有限公司 抗il-17抗体制剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001645A (zh) * 2004-08-05 2007-07-18 诺瓦提斯公司 Il－17拮抗抗体
CN101646690A (zh) * 2006-08-11 2010-02-10 先灵公司 抗il-17a抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508214A1 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
JP5581323B2 (ja) 2008-09-29 2014-08-27 ロシュ グリクアート アクチェンゲゼルシャフト ヒトｉｌ１７に対する抗体およびその使用
WO2011056864A1 (en) 2009-11-05 2011-05-12 Anaptysbio, Inc. Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001645A (zh) * 2004-08-05 2007-07-18 诺瓦提斯公司 Il－17拮抗抗体
CN101646690A (zh) * 2006-08-11 2010-02-10 先灵公司 抗il-17a抗体

Also Published As

Publication number Publication date
JP2013537414A (ja) 2013-10-03
WO2012018767A2 (en) 2012-02-09
AU2011285922B2 (en) 2016-06-16
EP2601217B1 (en) 2017-06-14
US9328166B2 (en) 2016-05-03
ES2633145T3 (es) 2017-09-19
RU2013109397A (ru) 2014-09-10
RU2595385C2 (ru) 2016-08-27
CN103154026A (zh) 2013-06-12
EP2601217A4 (en) 2014-03-05
AU2011285922A1 (en) 2013-03-21
NZ607615A (en) 2015-03-27
US20130202591A1 (en) 2013-08-08
BR112013002831A2 (pt) 2016-11-01
WO2012018767A3 (en) 2012-05-10
EP2601217A2 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
CN103154026B (zh) 抗il-17的抗体
US20240294631A1 (en) Antibodies directed against interleukin-33 (il-33)
JP7721585B2 (ja) インターロイキン３６受容体（ｉｌ－３６ｒ）に対する抗体
CN101522716A (zh) 抗人il-4受体的高亲和力人抗体
RU2829846C2 (ru) Антитела, направленные против интерлейкина-33 (il-33)
HK1231082A1 (en) Antibodies directed against interleukin-33 (il-33)
HK1231082B (en) Antibodies directed against interleukin-33 (il-33)
HK1252009B (en) Antibodies directed against interleukin 36 receptor (il-36r)
HK1250941B (en) Antibodies directed against interleukin 36 receptor (il-36r)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant